INT86464

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2000
Last Reported 2010
Negated 5
Speculated 0
Reported most in Body
Documents 31
Total Number 31
Disease Relevance 10.23
Pain Relevance 10.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (LMOD1) cytoskeleton (LMOD1) cytoplasm (LMOD1)
Anatomy Link Frequency
muscle 5
striatum 2
body 2
plasma 1
neurons 1
LMOD1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Dopamine 2006 100.00 Very High Very High Very High
Opioid 5 100.00 Very High Very High Very High
antagonist 678 99.64 Very High Very High Very High
Inflammation 18 99.36 Very High Very High Very High
dopamine receptor 190 98.32 Very High Very High Very High
cytokine 32 98.32 Very High Very High Very High
agonist 696 98.16 Very High Very High Very High
Serotonin 32 97.40 Very High Very High Very High
Neurotransmitter 111 97.20 Very High Very High Very High
Enkephalin 2 96.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Muscle Rigidity 76 99.90 Very High Very High Very High
Hypokinesia 228 99.64 Very High Very High Very High
Parkinson's Disease 306 99.50 Very High Very High Very High
INFLAMMATION 21 99.36 Very High Very High Very High
Muscle Hypertonia 19 99.16 Very High Very High Very High
Movement Disorders 136 98.32 Very High Very High Very High
Dyskinesias 305 97.68 Very High Very High Very High
Galactorrhea 124 92.68 High High
Dystonia 171 90.84 High High
Disease 149 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These afferents induce greater reduction of dopamine/D1 interaction than the resting situation.
D1 Binding (interaction) of associated with dopamine
1) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.22 Pain Relevance 0.49
Thus one can hypothesize that dopamine/D1 interaction regulates muscle tone.
D1 Binding (interaction) of in muscle associated with dopamine
2) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.18 Pain Relevance 0.34
We suggest that the greater reduction of dopamine/D1 interaction may be caused by further impairment of presynaptic dopamine release by one or more of several neurotransmitters that are activated by proprioreceptive mechanisms with influences on presynaptic nigrostriatal dopaminergic terminals.
D1 Binding (interaction) of associated with neurotransmitter and dopamine
3) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.21 Pain Relevance 0.50
Additionally our hypothesis suggests that in patients with PD with strong unilateral muscular rigidity the binding of D1 ligands in PET will be asymmetric and increased contralaterally to the more rigid body side.
D1 Binding (binding) of in body associated with muscle rigidity
4) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.15 Pain Relevance 0.17
If dopamine/D1 interaction is strongly interrupted over prolonged time period, one can consider that muscle tone may increase as an ambient clinical state.
D1 Binding (interaction) of in muscle associated with dopamine
5) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.57 Pain Relevance 0.61
According to our model, the pathologic tone disinhibition may be a consequence of impaired dopamine/D1 interaction.
D1 Neg (impaired) Binding (interaction) of associated with dopamine
6) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.91 Pain Relevance 0.36
D1 and D2 receptors express distinct patterns of affinity to dopamine and interact differently with one another depending on synaptic concentrations of neurotransmitter (Zheng et al. 1999; Gerlach et al. 2003).
D1 Binding (interact) of associated with neurotransmitter and dopamine
7) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.25 Pain Relevance 0.66
According to the model proposed, failed dopamine/D1 interaction from receptor blockade leads to the disinhibition of muscular tone and the clinical appearance of rigidity, whereas interrupted dopamine/D2 interaction disables the acceleration of muscle contraction, causing slowness of movement or bradykinesia.


D1 Neg (failed) Binding (interaction) of in muscle associated with dopamine and hypokinesia
8) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.90 Pain Relevance 0.32
Our premise is that dopamine/D1 interaction reduces muscle tone, and the muscular hypertonicity in PD is the consequence of insufficient interaction between pathologically reduced resting nanomolar dopamine level and D1 receptors.
D1 Binding (interaction) of in muscle associated with muscle hypertonia and dopamine
9) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.27 Pain Relevance 0.31
Different drugs known to induce neuroleptic-associated parkinsonism share the properties of binding to both D1 and D2 receptors (Reimold et al. 2007).
D1 Binding (binding) of associated with parkinson's disease
10) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.87 Pain Relevance 0.30
The nanomolar concentrations of dopamine interact preferentially with D1 receptors (dissociation constant 740 nM (Niznik et al. 1986, p. 8401), whereas micromolar concentrations are needed for prominent D2 receptor activation (dissociation constant 117 ?
D1 Binding (interact) of associated with dopamine
11) Confidence 0.44 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.22 Pain Relevance 0.57
According to our model, D1 antagonists inhibit dopamine/D1 interactions, so that dopamine cannot realize its action on D1 receptors and cannot cause tone reduction.
D1 Binding (interactions) of associated with dopamine and antagonist
12) Confidence 0.39 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.65 Pain Relevance 0.63
According to our hypothesis rigidity appears due to diminished dopamine/D1 interaction whereas bradykinesia is a consequence of reduced dopamine/D2 interaction.
D1 Binding (interaction) of associated with dopamine and hypokinesia
13) Confidence 0.39 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.76 Pain Relevance 0.13
Thus the single nigral axon may influence both D1 and D2 receptors in the pool of striatal neurons responsible for movement activity of agonist–antagonist muscle pair.
D1 Binding (receptors) of in neurons associated with antagonist and agonist
14) Confidence 0.34 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0 Pain Relevance 0.49
Additionally our hypothesis suggests that in patients with PD with strong unilateral muscular rigidity the binding of D1 ligands in PET will be asymmetric and increased contralaterally to the more rigid body side.
D1 Binding (ligands) of in body associated with muscle rigidity
15) Confidence 0.34 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.15 Pain Relevance 0.17
The considered impaired dopamine/D1 interaction is confirmed by treatment efficacy of very low doses of levodopa, because low dosage treatment increases the D1-interacting nanomolar dopamine levels and restores the normal tone inhibition.
D1 Neg (impaired) Binding (interaction) of associated with dopamine
16) Confidence 0.33 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 1.01 Pain Relevance 0.36
Our premise is that dopamine/D1 interaction reduces muscle tone, and the muscular hypertonicity in PD is the consequence of insufficient interaction between pathologically reduced resting nanomolar dopamine level and D1 receptors.
D1 Binding (interaction) of in muscle associated with muscle hypertonia and dopamine
17) Confidence 0.33 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.26 Pain Relevance 0.37
D1 receptors interact with lower and D2 receptors with higher dopamine concentrations.
D1 Binding (interact) of associated with dopamine
18) Confidence 0.33 Published 2010 Journal J Neural Transm Section Abstract Doc Link PMC3000910 Disease Relevance 0 Pain Relevance 0.46
At the molecular biology and neuropharmacological levels, the hypothesis suggests that putative treatments need to consider both D1 and D2 activity for maximal therapeutic efficacy in most movement disorders.



D1 Binding (activity) of associated with movement disorders
19) Confidence 0.30 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.52 Pain Relevance 0.24
It has been proposed that the selective interaction of clozapine with dopamine D1, D2 and D4 and 5HT2 receptors results in a distinctive alteration in the function of pre- and post-synaptic dopamine elements, with the hyperprolactinemic effect being mediated by supra-pituitary action of the drug (Meltzer and Gudelsky 1992).
D1 Binding (interaction) of in pituitary associated with dopamine
20) Confidence 0.09 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.29 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox